A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)

This is a commercial study sponsored by Neurocrine Biosciences. We only require CRIS to help select potential participants. It is looking at the safety and efficacy of a new drug, NBI-1065845, in an MDD population who have not responded well to their current medication(s).